Nitric oxide-sensitive guanylyl cyclase is differentially regulated by nuclear and non-nuclear estrogen pathways in anterior pituitary gland

• Published in: PloS one 2011-12, Vol.6 (12), p.e29402-e29402
• Main Authors: Cabilla, Jimena P, Nudler, Silvana I, Ronchetti, Sonia A, Quinteros, Fernanda A, Lasaga, Mercedes, Duvilanski, Beatriz H
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; 17β-Estradiol; Animals; Biology; Breast cancer; Cell cycle; Cell death; Cell growth; Cell Nucleus - metabolism; Coronary vessels; Cyclic GMP; Destabilization; Estrogens; Estrogens - metabolism; Estrus cycle; Female; Gene expression; Guanylate cyclase; Guanylate Cyclase - genetics; Guanylate Cyclase - metabolism; HuR protein; Medicine; Messenger RNA; Nitric oxide; Nitric Oxide - metabolism; Phenols (Class of compounds); Pituitary (anterior); Pituitary gland; Pituitary Gland, Anterior - metabolism; Polymerase Chain Reaction; Prostate cancer; Proteins; Rats; Rats, Wistar; Receptors, Estrogen - metabolism; RNA, Messenger - genetics; Rodents; Sex hormones; Transcription; Transcription, Genetic
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0029402

17β-estradiol (E2) regulates hormonal release as well as proliferation and cell death in the pituitary. The main nitric oxide receptor, nitric oxide sensitive- or soluble guanylyl cyclase (sGC), is a heterodimer composed of two subunits, α and β, that catalyses cGMP formation. α1β1 is the most abundant and widely expressed heterodimer, showing the greater activity. Previously we have shown that E2 decreased sGC activity but exerts opposite effects on sGC subunits increasing α1 and decreasing β1 mRNA and protein levels. In the present work we investigate the mechanisms by which E2 differentially regulates sGC subunits' expression on rat anterior pituitary gland. Experiments were performed on primary cultures of anterior pituitary cells from adult female Wistar rats at random stages of estrous cycle. After 6 h of E2 treatment, α1 mRNA and protein expression is increased while β1 levels are down-regulated. E2 effects on sGC expression are partially dependent on de novo transcription while de novo translation is fully required. E2 treatment decreased HuR mRNA stabilization factor and increased AUF1 p37 mRNA destabilization factor. E2-elicited β1 mRNA decrease correlates with a mRNA destabilization environment in the anterior pituitary gland. On the other hand, after 6 h of treatment, E2-BSA (1 nM) and E2-dendrimer conjugate (EDC, 1 nM) were unable to modify α1 or β1 mRNA levels, showing that nuclear receptor is involved in E2 actions. However, at earlier times (3 h), 1 nM EDC causes a transient decrease of α1 in a PI3k-dependent fashion. Our results show for the first time that E2 is able to exert opposite actions in the anterior pituitary gland, depending on the activation of classical or non-classical pathways. Thus, E2 can also modify sGC expression through membrane-initiated signals bringing to light a new point of regulation in NO/sGC pathway.